0152 GMT February 20, 2019
Overall, the drug pembrolizumab had significant benefits for patients, with 37 percent of patients who received it surviving for a year or more, compared with only 26.5 percent of those on standard care.
But the results were particularly exciting among the group of people who did respond to pembrolizumab – with a median length of response of 18.4 months, compared with five months for standard care.
The large international clinical trial was led by a team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 97 medical centers in 20 countries.
The trial was sponsored and funded by Merck and Co., Inc., known as MSD outside the United States and Canada, and the results are published in The Lancet today.
The drug was evaluated in a trial of nearly 500 patients with very advanced head and neck cancer that had spread around the body and had already become resistant to platinum chemotherapy, the first-line treatment for the disease. Some 247 patients were randomized to pembrolizumab and 248 to standard of care – chemotherapy or the targeted agent cetuximab.
When chemotherapy or targeted therapies stop working, treatment options for people with advanced head and neck cancer are limited, and they are normally expected to survive for less than six months.
Patients on the trial who received pembrolizumab survived for a median of 8.4 months with pembrolizumab, and 6.9 months with standard treatment.
But a minority of patients responded extremely well to pembrolizumab – 36 patients saw their cancer partially or completely disappear, and some are still cancer free three years after first receiving the drug.
Pembrolizumab also caused fewer serious side-effects than currently approved drugs – 13 percent of people who received the immunotherapy experienced serious side-effects, compared with 36 percent of people given standard treatment.
Researchers at The Institute of Cancer Research (ICR) and The Royal Marsden hope pembrolizumab could be a much needed smarter, kinder treatment option for people with advanced head and neck cancer.
Pembrolizumab works by taking the brakes off the immune system's ability to attack cancer cells, and is already approved for use in some people with lung cancer, skin cancer and lymphoma.
Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, and Consultant at The Royal Marsden NHS Foundation Trust, said:
"Head and neck cancer is extremely hard to treat once it comes back or spreads, and the outlook for patients once other therapies have stopped working is very poor.
"Our findings show that the immunotherapy pembrolizumab extends the life of people with advanced head and neck cancer overall, and in a group of patients has really dramatic benefits. It is also a much kinder treatment than those currently approved.
"I would like to see pembrolizumab approved for use in the clinic, so that people with advanced head and neck cancer can be offered the chance of a longer life and improved quality of life. There is also an urgent need to work out how we can identify in advance which patients are likely to benefit, given that some of these people may do much better than they do on standard treatment."
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
"Immunotherapies are already revolutionizing treatment for several cancer types, and I am excited to see the new drug pembrolizumab now showing benefit in advanced head and neck cancer.